Captrust Financial Advisors Arcus Biosciences, Inc. Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$17.23 - $37.73 $28,601 - $62,631	1,660 Added 402.91%	2,072 $53,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $2,111 - $3,053	-73 Reduced 15.05%	412 $13,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $4,675 - $7,222	149 Added 44.35%	485 $20,000
Q3 2021 Nov 16, 2021	BUY	$26.93 - $37.68 $350 - $489	13 Added 4.02%	336 $12,000
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $295 - $465	-13 Reduced 3.87%	323 $9,000
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $10,411 - $16,473	-398 Reduced 54.22%	336 $9,000
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $12,478 - $23,752	734 New	734 $19,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.